-- 
Ageas, Eiffage, GlaxoSmithKline, UCB: Europe Equity Preview

-- B y   J e f f   S u t h e r l a n d
-- 
2011-05-06T04:01:00Z

-- http://www.bloomberg.com/news/2011-05-05/ageas-eiffage-glaxosmithkline-ucb-europe-equity-preview.html
The following companies’ shares may
have unusual moves in European trading. Stock symbols are in
parentheses.  The Stoxx Europe 600 Index lost 0.3 percent to 277.79. The
Stoxx 50 Index fell 0.2 percent to 2,608.68. The Euro Stoxx 50
Index, a benchmark for nations using the euro, dropped 0.9
percent to 2,926.54.  Ageas (AGS)  : The insurer formerly known as Fortis said
it will appeal a ruling by the Rotterdam District Court, which
upheld a 576,000 euro ($837,000) fine levied by the Dutch market
regulator. Ageas dropped 0.5 percent to 2.01 euros.  Corio NV (CORA)  : The largest Dutch real-estate company
said first-quarter profit excluding items rose 18 percent as
acquisitions and rent increases lifted revenue. Corio shares
advanced 0.3 percent to 47.57 euros.  EDP-Energias de  Portugal  SA (EDP PL): Portugal’s biggest
power company said first-quarter net income rose 11 percent to
342 million euros partly on higher output from wind energy
projects. The stock dropped 1.1 percent to close at 2.67 euros.  Eiffage SA (FGR)  : The construction company said that
first-quarter sales rose to 2.99 billion euros from 2.91 billion
euros and that orders were in line with forecasts. Shares fell
1.4 percent to 44.77 euros.  GlaxoSmithKline Plc (GSK)  : Chief Executive Officer
 Andrew Witty  said all options are open in the long term for the
Viiv Healthcare Ltd. venture, which specializes in HIV
treatments. The stock gained 0.3 percent to 1,310 pence.  Groupe Bruxelles Lambert SA (GBLB)  : The Belgian
investment firm controlled by billionaires  Albert Frere  and Paul
Desmarais reported first-quarter profit dropped to 11 million
euros from 20.1 million euros a year earlier because of costs
for unwinding derivatives. GBL retreated 0.1 percent to 66.61
euros.  Rexam Plc (REX)  : The world’s biggest beverage-can maker
reported a 9 percent increase in first-quarter can sales volume
outside  North America  as demand rose. The shares rose 0.5
percent to 385.4 pence.  UCB SA (UCB)  : The maker of the Cimzia rheumatoid
arthritis medicine said Schwarz Vermoegensverwaltung GmbH & Co
KG cut its stake to 2.97 percent of  voting rights  as of April 29
from 4.96 percent on Dec. 9. UCB decreased 0.6 percent to 31.12
euros.  Wendel (MF)  : The investment firm said first-quarter
revenue was 1.44 billion euros, compared with a pro-forma 1.2
billion euros, and said growth is recovering in mature markets.
The shares fell 1.3 percent to 81.97 euros.  To contact the reporter on this story:
Jeff Sutherland in New York at 
 jsutherlan13@bloomberg.net   To contact the editor responsible for this story:
Nick Baker at 
 nbaker7@bloomberg.net  